Gala vs Hers: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher & Publisher

Reviewed & updated August 14, 2026 · Cites primary sources (FDA, NEJM, CMS) · Not medical advice

54 providers verified independently·Independent research·How we rank →

Visit Gala - from $149/mo →or find your match

Hers beats Gala overall, scoring 7.3/10 vs 7.2/10. Published pricing is not a like-for-like monthly comparison: Gala is from $149/mo; Hers is $188 first month, then $298/mo. Choose Gala for tirzepatide-first patients who want a lower yearly-plan rate. Choose Hers for women who want a female-focused platform and can budget at l.

A side-by-side look at Gala and Hers to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Gala

#34 of 54

7.2/10

Telehealth platform focused on compounded tirzepatide, both microdose and full-dose tiers, alongside a brand-name semaglutide (Ozempic) path and a 'coming soon' Wegovy pill. Operated by AI Coaching, Inc. (Wilmington, DE), backed by OpenLoop-affiliated medical groups (a recognized US telehealth backend) and LegitScript verified. Differentiator: a dedicated 'Gala GLP-1 Tracker' iOS + Android app for in-treatment dosing, weight, and side-effect logging.

Visit Gala

Higher Rated

Hers

#30 of 54

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). Hers lists Wegovy pill, Foundayo, and Ozempic pill medication from $149, a Wegovy pen from $199, Zepbound from $299, and compounded options. A required Weight Loss Membership adds $39 in month one and $149/mo thereafter, so the all-in floor for a $149 medication path is $188 initially and $298/mo ongoing; exact product and dose prices vary.

Visit Hers

Feature	Gala	Hers
Why each one	The dedicated 'Gala GLP-1 Tracker' app on BOTH iOS and Android, paired with a $149/mo microdose tirzepatide tier on a yearly commitment plan; most compounded-only platforms offer neither a first-party tracking experience nor an explicit microdose pricing tier.	A major women-focused telehealth platform with a direct Novo Nordisk partnership (Wegovy pill from $149 and pen from $199 before required membership) and a Lilly partnership (Zepbound medication from $299) alongside compounded options.
Our Score	7.2/10	7.3/10
Headline Price	from $149/mo	$188 first month, then $298/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Tirzepatide-first patients who want a lower yearly-plan rate (microdose $149/mo or full-dose $179/mo) plus a dedicated iOS + Android tracker app for daily progress logging	Women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path
Watch out for	Brand-name Ozempic here is $1,299/mo, materially above NovoCare's Wegovy pen $199/mo for the first two 0.25 mg or 0.5 mg fills through December 31, 2026, then $349/mo at standard strengths or $399/mo for Wegovy HD; oral pill from $149/mo, dose-dependent and Hims/Hers pill medication from $149 or pen from $199 plus required membership. Buy brand-name elsewhere; Gala's value is its compounded tirzepatide.	Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings.
Ranking	#34	#30
Get started	Visit Gala	Visit Hers

Pros & Cons Compared

Gala

Pros

+Compounded tirzepatide is $149/mo microdose or $179/mo full-dose on the yearly plan; 3-month pricing is $169/mo microdose or $219/mo full-dose
+Dedicated 'Gala GLP-1 Tracker' on BOTH iOS and Android, first-party in-treatment logging is uncommon among compounded-only platforms
+OpenLoop-affiliated medical groups + LegitScript verification provide third-party accountability that many compounded-only platforms lack
+All 50 states, free shipping, no insurance required, 24/7 patient support claimed

Cons

−Brand-name Ozempic here is $1,299/mo, materially above NovoCare's Wegovy pen $199/mo for the first two 0.25 mg or 0.5 mg fills through December 31, 2026, then $349/mo at standard strengths or $399/mo for Wegovy HD; oral pill from $149/mo, dose-dependent and Hims/Hers pill medication from $149 or pen from $199 plus required membership. Buy brand-name elsewhere; Gala's value is its compounded tirzepatide.
−Tirzepatide-only on the compounded side, compounded semaglutide is NOT offered, a narrower medication menu than peers like Maximus, Ro, or Henry Meds
−Mixed Trustpilot reviews mention dosing inconsistencies and slow customer service responsiveness, verify your specific dose and batch with each refill
−Initial consultation is typically a sync video visit, but ongoing follow-ups are chat-based (no scheduled ongoing video access), and there are no published labs, no named medical director, no specialty obesity oversight
−Restrictive refund policy, Gala's published terms state 'IN NO EVENT SHALL YOU BE ISSUED A REFUND UPON CANCELLATION OF THE SUBSCRIPTION SERVICES' with a narrow exception for provider-initiated medical disqualification. No money-back guarantee. Read the published policy at galaglp1.com/refund-policy before enrolling on a commitment plan
−Newer brand under AI Coaching, Inc. (founded 2024 per LinkedIn), limited public company history; founders, founding year, and named medical director not publicly disclosed on galaglp1.com itself

Hers

Pros

+FDA-approved brand paths include Wegovy pill, Foundayo, and Ozempic pill medication from $149 and a Wegovy pen from $199; with the required membership, a $149 medication path totals $188 initially and $298/mo ongoing
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform, integrates weight loss with hormonal, skin, and wellness services

Cons

−Pending federal enforcement action against the parent company. On July 29, 2026 the FTC, joined by Utah and California acting through Los Angeles County Counsel, filed a complaint against Hims & Hers Health, Inc. in the U.S. District Court for the Northern District of California, alleging violations of the FTC Act and the Restore Online Shoppers' Confidence Act over subscription billing, cancellation friction, and sharing consumer health information with advertising platforms. Case status is Pending. These are allegations, not findings.
−Every medication figure excludes the required Weight Loss Membership ($39 first month, then $149/mo); exact product and dose prices can increase the total above the $188/$298 floor
−Support runs at big-platform scale, fine for routine refills, less personal if you want high-touch care
−Compounded pricing starts at $199/mo with stepped pricing at higher doses, budget for the dose you'll end up on, not the entry dose
−Zepbound medication starts at $299 before the required membership; that path totals $338 in month one and at least $448/mo ongoing, with exact dose pricing potentially higher

Our Verdict

Hers edges out Gala with a score of 7.3/10 vs 7.2/10. Published pricing is not a like-for-like monthly comparison: Gala is from $149/mo; Hers is $188 first month, then $298/mo. Choose Gala if you want: tirzepatide-first patients who want a lower yearly-plan rate (microdose $149/mo or full-dose $179/mo) plus a dedicated ios + android tracker app for daily progress logging. Choose Hers if you want: women who want a female-focused platform and can budget at least $188 initially and $298/mo ongoing for a $149 medication path.